• All sections
  • C - Chemistrymetallurgy
  • C07D - Heterocyclic compounds
  • C07D 211/34 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Patent holdings for IPC class C07D 211/34

Total number of patents in this class: 447

10-year publication summary

28
21
24
28
25
25
33
19
25
2
2017 2018 2019 2020 2021 2022 2023 2024 2025 2026

Principal owners for this class

Owner
All patents
This class
Incyte Corporation
1032
15
Zevra Therapeutics, Inc.
105
13
Incyte Holdings Corporation
660
12
Novartis AG
10511
11
Biogen MA Inc.
917
11
Nocion Therapeutics, Inc.
47
9
Boehringer Ingelheim International GmbH
4596
8
ReNAgade Therapeutics Management Inc.
48
8
Massachusetts Institute of Technology
10167
7
The General Hospital Corporation
4795
7
Takeda Pharmaceutical Company Limited
2709
7
The Broad Institute, Inc.
1881
7
Praxis Precision Medicines, Inc.
200
7
AstraZeneca AB
2834
6
Guangzhou Innocare Pharma Tech Co., Ltd.
12
6
ChemoCentryx, Inc.
376
5
The Regents of the University of Michigan
4812
4
Astellas Pharma Inc.
1048
4
H. Lee Moffitt Cancer Center and Research Institute, Inc.
991
4
Richter Gedeon Nyrt.
1628
4
Other owners 292